Frontline Science: Specialized proresolving lipid mediators inhibit the priming and activation of the macrophage NLRP3 inflammasome

The prototypic proinflammatory cytokine IL‐1β plays a central role in innate immunity and inflammatory disorders. The formation of mature IL‐1β from an inactive pro‐IL‐1β precursor is produced via nonconventional multiprotein complexes called the inflammasomes, of which the most common is the nucleotide‐binding domain leucine‐rich repeat‐containing protein 3 (NLRP3) inflammasome composed by NLRP3, (ASC) apoptosis‐associated speck‐like protein containing a caspase activation and recruitment domain (CARD), and caspase‐1. Specialized proresolving mediators (SPMs) promote resolution of inflammation, which is an essential process to maintain host health. SPMs prevent excessive inflammation by terminating the inflammatory response and returning to tissue homeostasis without immunosupression. This study tested the hypothesis that modulation of the NLRP3 inflammasome in macrophages is one mechanism involved in the SPM‐regulated processes during resolution. Our findings demonstrate that the SPM resolvin D2 (RvD2) suppressed the expression of pro‐IL‐1β and reduced the secretion of mature IL‐1β in bone marrow‐derived macrophages challenged with LPS+ATP (classical NLRP3 inflammasome model) or LPS+palmitate (lipotoxic model). Similar findings were observed in thioglycolate‐elicited peritoneal macrophages, in which RvD2 remarkably reduced ASC oligomerization, inflammasome assembly, and caspase‐1 activity. In vivo, in a self‐resolving zymosan A‐induced peritonitis model, RvD2 blocked the NLRP3 inflammasome leading to reduced release of IL‐1β into the exudates, repression of osteopontin, and MCP‐1 expression and induction of M2 markers of resolution (i.e., CD206 and arginase‐1) in peritoneal macrophages. RvD2 inhibitory actions were receptor mediated and were abrogated by a selective GPR18 antagonist. Together, these findings support the hypothesis that SPMs have the ability to inhibit the priming and to expedite the deactivation of the NLRP3 inflammasome in macrophages during the resolution process. Resolvin D2 modulates the NLRP3 inflammasome and the production of IL‐1β in macrophages during resolution of inflammation.